OZEM - ETF AI Analysis

Top Page

Roundhill GLP-1 & Weight Loss ETF (OZEM)

Rating:61Neutral

Price Target:―

OZEM, the Roundhill GLP-1 & Weight Loss ETF, has a solid but not top-tier rating, mainly driven by its large positions in established drug makers like Novo Nordisk and Eli Lilly, which benefit from strong financial performance and strategic focus on long-term growth in weight-loss treatments. Additional support comes from quality holdings such as Amgen, Pfizer, Roche, and Chugai, though concerns about overvaluation, high debt, and some short-term challenges temper the overall picture. Weaker, more speculative biotech names like Structure Therapeutics and Ascletis Pharma, which face ongoing losses and financial sustainability risks, add volatility and highlight the fund’s main risk: concentrated exposure to a single, specialized healthcare theme with a mix of mature and high-risk early-stage companies.

Positive Factors

Strong Recent Performance

The ETF has shown strong gains over the last three months and solid year-to-date results, indicating positive recent momentum.

Leading GLP-1 Drug Makers at the Top

Large positions in major GLP-1 and weight-loss drug companies like Novo Nordisk and Eli Lilly, which have generally performed well, help drive the fund’s returns.

Focused Yet Globally Spread Portfolio

While the fund is heavily focused on health care, it still spreads its holdings across several countries, reducing reliance on any single market.

Negative Factors

High Concentration in a Few Stocks

A significant portion of the portfolio is tied up in just a couple of large holdings, which increases the impact if those companies stumble.

Single-Sector Risk

With almost all assets in health care, the ETF is highly exposed to sector-specific risks like regulatory changes or negative drug news.

Above-Average Expense Ratio

The fund’s expense ratio is relatively high for an ETF, which means more of the returns are eaten up by fees over time.

OZEM Historical Chart

AUM60.00M

RegionGlobal

Expense Ratio0.59%

Beta0.79

IssuerRoundhill

Inception DateMay 21, 2024

Dividend Yield1.14%

Asset ClassEquity

Index TrackedNo Underlying Index

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume34,841

30 Day Avg. Volume25,128

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

43.30

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering23

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

OZEM Summary

The Roundhill GLP-1 & Weight Loss ETF (OZEM) is a health care fund focused on companies working on weight-loss drugs and treatments for obesity and related conditions. It doesn’t track a traditional index, but instead targets drugmakers and biotech firms leading this theme, including well-known names like Novo Nordisk and Eli Lilly. Someone might invest in OZEM if they believe new weight-loss medicines will keep growing in demand and want a simple way to spread their money across several companies in this space. A key risk is that it’s heavily concentrated in health care and can rise or fall sharply with news about drug trials, regulations, or pricing.

How much will it cost me?The Roundhill GLP-1 & Weight Loss ETF (OZEM) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a niche sector like pharmaceuticals and biotechnology, which requires more research and specialized management.

What would affect this ETF?The Roundhill GLP-1 & Weight Loss ETF could benefit from growing global demand for innovative health solutions, particularly in obesity and metabolic disorder treatments, as well as advancements in biotechnology and pharmaceuticals led by top holdings like Novo Nordisk and Eli Lilly. However, potential risks include regulatory hurdles, competition in the weight management sector, and broader economic challenges that may impact healthcare spending or innovation funding. Global exposure also means the ETF could be affected by geopolitical events or currency fluctuations.

OZEM Top 10 Holdings

OZEM is essentially a bet on the global GLP-1 and obesity drug boom, with Novo Nordisk and Eli Lilly in the driver’s seat: both have been rising or steady, and their heavyweight positions mean they do most of the lifting for the fund. High-flyer Structure Therapeutics and Ascletis add a more speculative punch, recently surging but with shakier fundamentals. On the flip side, Viking Therapeutics has been losing steam, acting as a small drag. Overall, this is a health care–heavy, globally diversified play tightly focused on weight-loss innovation.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
NVO	Novo Nordisk	21.86%	$13.12M	$260.74B	-28.09%	73 Outperform
LLY	Eli Lilly & Co	14.68%	$8.81M	$980.50B	27.98%	72 Outperform
GPCR	Structure Therapeutics, Inc. Sponsored ADR	4.92%	$2.95M	$5.37B	195.13%	31 Underperform
ROG	Roche Holding AG	4.38%	$2.63M	CHF279.83B	41.18%	73 Outperform
4519	Chugai Pharmaceutical Co	4.08%	$2.45M	¥14.47T	27.44%	74 Outperform
PFE	Pfizer	4.03%	$2.42M	$150.33B	0.92%	74 Outperform
	―	3.94%	$2.36M	―	―	―
1672	Ascletis Pharma, Inc.	3.88%	$2.33M	HK$13.69B	240.74%	54 Neutral
AMGN	Amgen	3.55%	$2.13M	$184.10B	18.35%	77 Outperform
VKTX	Viking Therapeutics	3.45%	$2.07M	$3.28B	-7.87%	53 Neutral

OZEM Technical Analysis

Technical Analysis Sentiment

Positive

Last Price―

Price Trends

50DMA

34.37

Positive

100DMA

31.20

Positive

200DMA

28.02

Positive

Market Momentum

MACD

0.60

Positive

RSI

56.23

Neutral

STOCH

37.41

Neutral

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For OZEM, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 35.87, equal to the 50-day MA of 34.37, and equal to the 200-day MA of 28.02, indicating a bullish trend. The MACD of 0.60 indicates Positive momentum. The RSI at 56.23 is Neutral, neither overbought nor oversold. The STOCH value of 37.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OZEM.

OZEM Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
OZEM	―	―	$60.00M	0.59%	―
FMED	―	―	$62.83M	0.50%	―
HRTS	―	―	$56.62M	0.75%	―
MEDI	―	―	$26.53M	0.80%	―
GDOC	―	―	$21.14M	0.75%	―
PSIL	―	―	$19.85M	1.00%	―

Performance Comparison

OZEM

Roundhill GLP-1 & Weight Loss ETF

35.97

11.84

49.07%

FMED

Fidelity Disruptive Medicine ETF

―

HRTS

Tema Cardiovascular and Metabolic ETF

―

MEDI

Harbor Health Care ETF

―

GDOC

Goldman Sachs Future Health Care Equity ETF

―

PSIL

AdvisorShares Psychedelics ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents